Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1478-6362
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic) ; volume:23 ; number:1 ; day:3 ; month:3 ; year:2021 ; pages:1-11 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (3.3.2021), 1-11, 12.2021

Creator
Hamidou, Mohamed
Néel, Antoine
Poupon, Joel
Amoura, Zahir
Ebbo, Mikael
Sibilia, Jean
Viallard, Jean-Francois
Gaborit, Benjamin
Volteau, Christelle
Hardouin, Jean Benoit
Hachulla, Eric
Rieger, François
Contributor
SpringerLink (Online service)

DOI
10.1186/s13075-021-02454-6
URN
urn:nbn:de:101:1-2021041707402012995759
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Hamidou, Mohamed
  • Néel, Antoine
  • Poupon, Joel
  • Amoura, Zahir
  • Ebbo, Mikael
  • Sibilia, Jean
  • Viallard, Jean-Francois
  • Gaborit, Benjamin
  • Volteau, Christelle
  • Hardouin, Jean Benoit
  • Hachulla, Eric
  • Rieger, François
  • SpringerLink (Online service)

Other Objects (12)

PML-RARA mutations confer varying arsenic trioxide resistance

PML-RARA mutations confer varying arsenic trioxide resistance

Arsenic trioxide uptake by hexose permeases in Saccharomyces cerevisiae

Arsenic trioxide uptake by hexose permeases in Saccharomyces cerevisiae

Oxidative stress induced by the chemotherapeutic agent arsenic trioxide

Oxidative stress induced by the chemotherapeutic agent arsenic trioxide

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Metal–organic framework nanoparticles for arsenic trioxide drug delivery

Metal–organic framework nanoparticles for arsenic trioxide drug delivery

Arsenic trioxide as a novel anti-glioma drug: a review

Arsenic trioxide as a novel anti-glioma drug: a review

Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse

Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse

Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study

Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study

Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells

Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells

Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide

Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9

PML and its degradation by arsenic trioxide in interferon-mediated neuro-inflammation

PML and its degradation by arsenic trioxide in interferon-mediated neuro-inflammation

Related objects